Search research articles
Contact Us
Filters
Showing results (11-20 of 50) with videos related to
Page
of 5
Sort By:
Nature Reviews. Drug Discovery
|
August 3, 2006
Strategies for optimizing combinations of molecularly targeted anticancer agents
Janet E Dancey, Helen X Chen
Seminars in Oncology
|
December 8, 2009
Evaluating temsirolimus activity in multiple tumors: a review of clinical trials
Janet E Dancey, Rafael Curiel, Joseph Purvis
Frontiers in Pharmacology
|
December 25, 2023
Minding the gaps: assessing and addressing clinical research core competencies across a network of Canadian cancer centres
Stephen Sundquist, Diana Kato, Raisa Chowdhury, et al.
The Lancet. Oncology
|
February 13, 2016
Rare cancers: a sea of opportunity
Niki Boyd, Janet E Dancey, C Blake Gilks, et al.
Cell
|
February 7, 2012
The genetic basis for cancer treatment decisions
Janet E Dancey, Philippe L Bedard, Nicole Onetto, et al.
Current Oncology (Toronto, Ont.)
|
April 21, 2022
The Impact of COVID-19 on Academic Cancer Clinical Trials in Canada and the Initial Response from Cancer Centers
Stephen Sundquist, Diana Kato, Rebecca Y Xu, et al.
Current Oncology (Toronto, Ont.)
|
August 26, 2021
Advancing Academic Cancer Clinical Trials Recruitment in Canada
Rebecca Y Xu, Diana Kato, Gregory R Pond, et al.
Journal of the National Cancer Institute
|
October 27, 2009
A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment
Sheila E Taube, Gary M Clark, Janet E Dancey, et al.
Cancers
|
December 30, 2025
The Outcome and Impact of Academic Cancer Clinical Trials with Participation from Canadian Sites (2015-2024)
Rebecca Y Xu, Diana Kato, Victoria Percival, et al.
Leukemia Research
|
March 6, 2009
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma
Sherif S Farag, Shuhong Zhang, Buffy S Jansak, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 50) with videos related to
Sort By:
Page
of 5
Nature Reviews. Drug Discovery
|
August 3, 2006
Strategies for optimizing combinations of molecularly targeted anticancer agents
Janet E Dancey, Helen X Chen
Seminars in Oncology
|
December 8, 2009
Evaluating temsirolimus activity in multiple tumors: a review of clinical trials
Janet E Dancey, Rafael Curiel, Joseph Purvis
Frontiers in Pharmacology
|
December 25, 2023
Minding the gaps: assessing and addressing clinical research core competencies across a network of Canadian cancer centres
Stephen Sundquist, Diana Kato, Raisa Chowdhury, et al.
The Lancet. Oncology
|
February 13, 2016
Rare cancers: a sea of opportunity
Niki Boyd, Janet E Dancey, C Blake Gilks, et al.
Cell
|
February 7, 2012
The genetic basis for cancer treatment decisions
Janet E Dancey, Philippe L Bedard, Nicole Onetto, et al.
Current Oncology (Toronto, Ont.)
|
April 21, 2022
The Impact of COVID-19 on Academic Cancer Clinical Trials in Canada and the Initial Response from Cancer Centers
Stephen Sundquist, Diana Kato, Rebecca Y Xu, et al.
Current Oncology (Toronto, Ont.)
|
August 26, 2021
Advancing Academic Cancer Clinical Trials Recruitment in Canada
Rebecca Y Xu, Diana Kato, Gregory R Pond, et al.
Journal of the National Cancer Institute
|
October 27, 2009
A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment
Sheila E Taube, Gary M Clark, Janet E Dancey, et al.
Cancers
|
December 30, 2025
The Outcome and Impact of Academic Cancer Clinical Trials with Participation from Canadian Sites (2015-2024)
Rebecca Y Xu, Diana Kato, Victoria Percival, et al.
Leukemia Research
|
March 6, 2009
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma
Sherif S Farag, Shuhong Zhang, Buffy S Jansak, et al.
Page
of 5